C8 Substandard and Falsified (SF) medical products: Safeguarding the supply chain, protecting people

Tuesday 12 September 2017
COEX Convention & Exhibition Center : Grand Ballroom 103 3 hours

Organised by the FIP Hospital Pharmacy Section, the FIP Military and Emergency Pharmacy Section and the FIP Industrial Pharmacy Section

Chairs: Nkechi Christiana Anyanwu (Federal Medical Centre, Nigeria) and K.H. Chung (Sungkyunkwan University, Republic of Korea)


Substandard and Falsified (SF) medical products are a global challenge to the pharmaceutical supply chain. SF medical products compromise the distribution of high quality medicines, putting patient safety at risk. This session will clarify what constitutes “counterfeit” medicines, show the global scope of the problem and potential effects on patient outcomes. Measures to forensically combat existing and potential counterfeit products, as coordinated by the WHO, will be presented. A global overview of legislative measures to prevent counterfeit drugs will be presented and the underlying approaches will be discussed.

Learning objectives

At the conclusion of this application-based session, participants will be able to:

  1. Differentiate Substandard and Falsified (SF) medical products
  2. Advocate the WHO Global Surveillance and Monitoring System
  3. Evaluate various legislative measures securing the pharmaceutical supply chain
  4. Detect weaknesses in the supply chain of their own practice.


14:30 – 14:40
1. Introduction by the chairs

14:40 – 15:15
2.  The loopholes in SF medical products because of the scale of production
Mike Anisfeld (Globepharm, USA)

15:15 – 15:50
3.  WHO Global Surveillance and Monitoring
Diana Lee (World Health Organization, Switzerland)

15:50 – 16:10 Coffee/tea break 

16:10 – 16:45

4.  A world tour of measures to stop SF medical products at governmental level
Robert Moss (European Association of Hospital Pharmacists, Netherlands)

16:45 – 17:20
5.  Experience on the practical aspects of identifying counterfeit medicines in the field

Trudi Hilton (WHO / University of London, UK)

17:20 – 17:30
6. Conclusions